Wave Life Sciences Announces Two Papers in the Journal Nucleic Acids Research Describing How PN Backbone Chemistry Modifications Enhance the Pharmacological Effects of Oligonucleotides
February 02, 2022 16:05 ET
|
Wave Life Sciences USA, Inc.
Wave paper on PN chemistry for silencing in the CNS, and the implications for oligonucleotides more broadly, designated as a Breakthrough Article by Nucleic Acids Research Publications highlight the...
Imara Presents Preclinical Data on IMR-261 at the American Society of Hematology (ASH) Annual Meeting 2021
December 14, 2021 07:00 ET
|
Imara, Inc.
Oral presentation provides first look at new program, IMR-261, a novel, oral, clinic-ready nuclear factor erythroid 2-related factor 2 (Nrf2) activator SCD Townes mouse model demonstrates IMR-261...
Cocrystal Pharma Presents Preclinical Data from COVID-19 Antiviral Programs and Outlines Near-Term Clinical Plans at the World Antiviral Congress 2021
December 01, 2021 16:05 ET
|
Cocrystal Pharma, Inc.
Unveils designs for Phase 1 and 2 studies with intranasal/pulmonary and oral SARS-CoV-2 protease inhibitors; trial initiations expected in 2022 BOTHELL, Wash., Dec. 01, 2021 (GLOBE NEWSWIRE) --...
Rubius Therapeutics Announces Preclinical Data for RTX-224, a Broad Immune Costimulatory Agonist, to be Presented at the Society for Immunotherapy of Cancer’s Annual Meeting
October 01, 2021 08:00 ET
|
Rubius Therapeutics
CAMBRIDGE Mass., Oct. 01, 2021 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an...
Wave Life Sciences Reports Second Quarter 2021 Financial Results and Provides Business Update
August 05, 2021 07:30 ET
|
Wave Life Sciences USA, Inc.
Dosing underway in FOCUS-C9 clinical trial of WVE-004 in C9-ALS / C9-FTD – first oligonucleotide using PN backbone chemistry modifications in clinical study Recruitment ongoing for clinical trials in...
Wave Life Sciences Announces Proof-of-Concept Preclinical Data for ADAR Editing Program in Alpha-1 Antitrypsin Deficiency
June 02, 2021 16:52 ET
|
Wave Life Sciences USA, Inc.
First proof-of-concept in vivo data for RNA editing using endogenous ADAR enzymes in alpha-1 antitrypsin deficiency ADAR editing resulted in therapeutically meaningful restoration of circulating...
Rubius Therapeutics Announces Publication of RTX-321 Preclinical Data in Nature Communications
May 12, 2021 08:00 ET
|
Rubius Therapeutics
CAMBRIDGE, Mass., May 12, 2021 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an...
Auris Medical Announces Positive Preclinical and Clinical Outcomes with AM-301 and Details Plans for Market Launch
April 13, 2021 07:45 ET
|
Auris Medical AG
Clinical evaluation of AM-301 nasal spray in allergic rhinitis meets primary endpoint Extended protection achieved over several hoursPreliminary preclinical data suggest therapeutic utility post...
Pandion Therapeutics Presents Preclinical Data Highlighting Potential of Tissue-Tethered PD-1 Agonist to Locally Target Autoimmune Disease at the nPOD 13th Annual Scientific Meeting
February 22, 2021 08:30 ET
|
Pandion Therapeutics, Inc.
WATERTOWN, Mass., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Pandion Therapeutics, Inc. (Nasdaq: PAND), a clinical-stage biotechnology company developing novel therapeutics designed to address the unmet...
Wave Life Sciences Highlights Pipeline Progress and Expansion Leveraging New PN Backbone Chemistry Modifications
January 11, 2021 08:00 ET
|
Wave Life Sciences USA, Inc.
Three clinical trials to begin in 2021 with compounds containing Wave’s novel PN backbone chemistry modifications Data from ongoing PRECISION-HD and OLE clinical trials for Huntington’s disease...